RNA sequencing of sputum cells from a phase IIa placebo controlled clinical trial of Risankizumb in severe asthma

Interleukin (IL)-23 is implicated in T2 and T17-mediated airway inflammation, supporting a role in asthma. We undertook a Phase II, randomized, double-blind, placebo-controlled, 24-week, parallel-group, multicenter trial to assess the efficacy and safety of risankizumab, an IL23p19 monoclonal antibody, administered subcutaneously (90 mg 4 weekly) in adults with severe asthma. Sputum samples were collected at several timepoints: visit 1B (week -3), visit 2 (week 0 proir to treatment), visit 7 (week 20), visit 8 (week 24, end of treatment), visit 12 (week 40, end of observation). RNA sequencing of sputum cells. Comparison of sputum cells from asthma patients treated with either placebo or Risankizumab.

白细胞介素(Interleukin, IL)-23参与介导2型(T2)及17型(T17)辅助T细胞相关的气道炎症，提示其在哮喘发病过程中发挥作用。本研究开展一项II期、随机、双盲、安慰剂对照、为期24周的平行组多中心临床试验，旨在评估瑞莎珠单抗(risankizumab，一种IL-23p19单克隆抗体)皮下给药（90mg，每4周1次）治疗重度哮喘成人患者的疗效与安全性。研究在多个时间点采集痰液样本：访视1B（第-3周）、访视2（治疗前第0周）、访视7（第20周）、访视8（第24周，治疗结束时）及访视12（第40周，观察结束时）。对痰液细胞进行RNA测序(RNA sequencing)，并对比接受安慰剂或瑞莎珠单抗治疗的哮喘患者的痰液细胞差异。